



Bayer AG
Communications
51368 Leverkusen
Germany
Phone +49 214 30-1
www.bayer.com/en/media

News Release

Monsanto reaches agreements in principle to resolve additional PCB cases at the Sky Valley Education Center

- Agreements resolve all Sky Valley cases, involving more than 200 plaintiffs, except prior adverse verdicts that remain on appeal
 - Settlement is covered by the PCB-related provision taken in Q2, 2025
-

Leverkusen, August 18, 2025 – Monsanto has now reached agreements in principle to resolve all Sky Valley Education Center cases, representing more than 200 plaintiffs overall, with the exception of the prior adverse verdicts that remain on appeal. The Sky Valley Education Center cases involve allegations of injuries due to exposure to polychlorinated biphenyls (PCBs) at the school campus in Washington state.

The terms of the agreements in principle are confidential and subject to approval of final settlement agreements by the parties. The cost of the additional settlements is covered by the PCB litigation provision taken in Q2, which also covers the previously announced settlement of the *Burke* case as well as other PCB-related litigation costs. While the company remains confident in its legal strategy and defenses, and is fully prepared to defend cases at trial, it has maintained it will consider resolving cases on appropriate terms when it is strategically advantageous to help mitigate the risks and uncertainties of this litigation. The company continues to pursue a multi-pronged strategy to significantly contain the risks of this litigation by the end of 2026.

The adverse jury decisions in nine prior cases (49 plaintiffs) remain under appeal and are not included in the settlement agreements. Each of these cases has its own unique factual and legal record, and all of these appeals raise additional questions of law that are not before the Washington State Supreme Court in *Erickson*, a case that is still pending.

The company filed a complaint in Missouri to enforce its rights under indemnity contracts signed in 1972 by its largest, former electrical manufacturing customers. Under these agreements, these former customers agreed to fully defend and indemnify Monsanto as a condition of continuing to receive bulk PCBs for use in their closed-end finished products.

Widely recognized as nonflammable safety fluids, PCBs were once specified by many electrical and building codes and insurance companies to protect against serious fire risk, and their production was required by the federal government to protect the nation's electrical grid. In 1972, the Interdepartmental Task Force on PCBs, comprised of eight federal agencies and sub-agencies, including EPA, found that continued manufacture and sale of PCBs for certain electrical applications was necessary. Monsanto voluntarily ceased all PCB production in 1977.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contact for media inquiries:

Brian Leake, phone +1 314-370-3285

Email: brian.leake@bayer.com

Philipp Blank, phone +49 214 30-20499

Email: philipp.blank@bayer.com

Contact for investor inquiries:

Bayer Investor Relations Team, phone +49 214 30-72704

Email: ir@bayer.com

www.bayer.com/en/investors/ir-team

pb (2025-0155E)

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to "Bayer" or "the company" herein may refer to one or more subsidiaries as context requires.